ABBOTT EXTENDING INFUSION PUMP LINE
ABBOTT EXTENDING INFUSION PUMP LINE with LifeCare 1500 ambulatory microinfuser, developed and manufactured by Parker Hannifin, Abbott an- nounced in a May 15 release. Abbott said it "signed an agreement to market an ambulatory medication infusion pump developed by Parker Hannifin. . .to further extend its leading line of products that deliver intravenous fluids and drugs to patients electronically." Parker Hannifin said that Abbott would have exclusive marketing rights to the device as long as certain undisclosed conditions are met. Parker Hannifin will produce the device, which will either be leased or sold to physicians and hospitals at a cost ranging between $1,400 and $2,000, for Abbott. The microinfusion pump, Abbott's fourth electronic flow device in the LifeCare line, will be marketed separately from Abbott drug products, the firm said. Abbott's other pump devices include the LifeCare Model 4 pump, micro pump, 1050 volumetric controller, and a patient-controlled analgesia system. The programmable electronic infusion device, approved by the FDA 16 months ago, "will be used to provide drugs to patients being treated for cancer, pain and infectious diseases," the release states. The device is "smaller than a business card" and weighs "less than 2-1/2 ounces," according to the release.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: